1 / 21

TOC - Global Hematological Malignancies Emerging Therapeutics Market

The global hematological malignancies emerging therapeutics industry analysis by BIS Research projects the market to grow at a significant CAGR of 14.20% during the forecast period 2021-2031.

swati8
Download Presentation

TOC - Global Hematological Malignancies Emerging Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Hematological Malignancies Emerging Therapeutics Market - A Global and Regional Analysis Table of Content Hematological Malignancies Emerging Therapeutics Market Focus on Therapeutic Type (Marketed), Potential Pipeline Products, Indication, and Region Analysis and Forecast: 2021-2031 February 2022 All rights reserved at BIS Research Inc. 1

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Hematological Malignancies Emerging Therapeutics Market Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. All rights reserved at BIS Research Inc. 2

  3. Table of Content Executive Summary .......................................................................... 20 1.Market ....................................................................................... 26 1.1 Product Definition ............................................................................................ 27 1.1.1Monoclonal Antibody (mAB) Therapy: Hematological Malignancies ..... 27 1.1.2CAR-T Cell Therapy: Hematological Malignancies ................................... 27 1.1.3Inclusion and Exclusion ............................................................................. 27 1.2 Market Scope ................................................................................................... 27 1.2.1Key Questions Answered in the Report .................................................... 28 1.3 Research Methodology ................................................................................... 29 1.3.1Global Hematological Malignancy Emerging Therapeutics Market: Research Methodology ............................................................................... 29 1.3.2Data Sources ............................................................................................... 30 1.3.2.1 Primary Data Sources ........................................................................................ 30 1.3.2.2 Secondary Data Sources ................................................................................... 31 1.3.3Market Estimation Model ............................................................................ 32 1.3.4Criteria for Company Profiling ................................................................... 34 1.4 Market Overview .............................................................................................. 34 1.4.1Market Definition ......................................................................................... 34 Hematological Malignancies Emerging Therapeutics Market 1.4.2Market Footprint and Growth Potential, $Million, 2020-2031 ................... 35 1.4.3Epidemiology of Hematological Malignancies .......................................... 36 1.4.3.1 U.S. Epidemiology of Hematological Malignancies ........................................... 37 1.4.3.2 Epidemiology of Hematological Malignancies (Germany, France, Italy, and Spain (EU4) + U.K.) ........................................................................................... 38 1.4.3.3 Japan Epidemiology of Hematological Malignancies ......................................... 42 1.4.4Pipeline Analysis ......................................................................................... 43 1.4.4.1 By Clinical Phase ............................................................................................... 43 1.4.4.2 By Indication ...................................................................................................... 44 1.4.4.2.1Leukemia .................................................................................................................. 44 1.4.4.2.2Lymphoma ............................................................................................................... 45 All rights reserved at BIS Research Inc. 3

  4. 1.4.4.2.3Multiple Myeloma (MM) ............................................................................................ 46 1.4.5Impact of COVID-19 on Global Hematological Malignancies Emerging Therapeutics Market .................................................................. 46 1.4.5.1 Interruption in Research and Clinical Development and Commercial Operation ........................................................................................................... 46 1.4.5.1.1Research and Clinical Development ........................................................................ 46 1.4.5.1.2Commercial Operation and Access ......................................................................... 47 1.4.5.2 Navigating Crisis Recovery and Looking to the Future ...................................... 47 2. Industry Analysis ...................................................................... 49 2.1 Overview ........................................................................................................... 50 2.2 Legal Requirements and Frameworks in the U.S. ......................................... 50 2.2.1Clinical Trial Authorization ......................................................................... 50 2.2.2Marketing Authorization ............................................................................. 50 2.2.3Post-Authorization Regulations ................................................................. 52 2.3 Legal Requirements and Frameworks in Europe .......................................... 53 2.3.1Centralized Procedure ................................................................................ 53 2.3.2Decentralized Procedure ............................................................................ 54 2.3.3Mutual-Recognition Procedure .................................................................. 54 2.3.4National Procedure ...................................................................................... 54 Hematological Malignancies Emerging Therapeutics Market 2.4 Legal Requirements and Frameworks in Asia-Pacific .................................. 54 2.4.1China ............................................................................................................ 54 2.4.2Japan ............................................................................................................ 55 2.5 Reimbursement Scenario ................................................................................ 56 2.5.1U.S. ............................................................................................................... 56 2.5.2Europe .......................................................................................................... 57 3. Market Dynamics ...................................................................... 59 3.1 Overview ........................................................................................................... 60 3.2 Impact Analysis ............................................................................................... 60 3.3 Market Drivers .................................................................................................. 61 3.3.1Growing Prevalence of Hematological Malignancies ............................... 61 All rights reserved at BIS Research Inc. 4

  5. 3.3.2Favorable Regulatory Environment ........................................................... 62 3.3.3Increase in Adoption of Precision Medicine in the Field of Hematological Malignancies ...................................................................... 63 3.4 Market Restraints ............................................................................................. 64 3.4.1High Cost Hindering the Adoption Rate .................................................... 64 3.4.2Unfavorable Reimbursement Scenario ...................................................... 64 3.4.3Safety Concerns Pertaining to Severe Adverse Effects ........................... 65 3.5 Market Opportunities ....................................................................................... 65 3.5.1Massive Scope in Emerging Markets ......................................................... 65 4.Competitive Landscape ............................................................. 66 4.1 Overview ........................................................................................................... 67 4.2 Key Developments and Strategies ................................................................. 68 4.2.1Partnerships and Alliances ........................................................................ 69 4.2.2Regulatory and Legal Activities ................................................................. 70 4.2.3Business Expansions ................................................................................. 71 4.2.4Merger and Acquisition Activities .............................................................. 72 4.2.5Product Approvals ...................................................................................... 73 4.2.6Funding Activities ....................................................................................... 74 4.3 Market Share Analysis, by Company (2020) .................................................. 75 Hematological Malignancies Emerging Therapeutics Market 5.Role of Companion Diagnostics .................................................. 77 5.1 Overview ........................................................................................................... 78 5.2 Drug-Diagnostic Co-Development ................................................................. 78 5.3 FDA-Approved Companion Diagnostic Tests for Hematological Malignancies .................................................................................................... 80 5.4 Regulatory Framework: Companion Diagnostics (CDx) .............................. 81 5.4.1Overview ...................................................................................................... 81 5.4.2Legal Requirements and Frameworks in the U.S. .................................... 81 5.4.3Legal Requirements and Frameworks in Europe ..................................... 84 5.4.4Legal Requirements and Frameworks in Asia-Pacific ............................. 87 5.4.4.1 China ................................................................................................................. 87 All rights reserved at BIS Research Inc. 5

  6. 5.4.4.2 Japan ................................................................................................................. 90 5.4.4.3 South Korea ....................................................................................................... 91 5.4.4.4 Australia ............................................................................................................. 93 6.Global Hematological Malignancies Emerging Therapeutics Market (by Marketed Drugs), $Million, 2020-2031 ....................... 95 6.1 Overview ........................................................................................................... 96 6.2 Monoclonal Antibodies ................................................................................... 97 6.2.1Blincyto (Blinatumomab) ............................................................................ 98 6.2.2Besponsa (Inotuzumab Ozogamicin) ......................................................... 99 6.2.3Lumoxiti (Moxetumomab Pasudotox) ...................................................... 101 6.2.4Mylotarg (Gemtuzumab Ozogamicin) ...................................................... 102 6.2.5Opdivo (Nivolumab) .................................................................................. 103 6.2.6AiRuiKa (Camrelizumab) ........................................................................... 104 6.2.7Tyvyt (Sintilimab) ....................................................................................... 105 6.2.8Tislelizumab ............................................................................................... 106 6.2.9Gazyva (Obinutuzumab) ........................................................................... 107 6.2.10Zynlonta (Loncastuximab Tesirine-lpyl) .................................................. 109 6.2.11Darzalex (Daratumumab) .......................................................................... 110 6.2.12Blenrep (Belantamab Mafodotin-blmf) ..................................................... 111 Hematological Malignancies Emerging Therapeutics Market 6.2.13Keytruda (Pembrolizumab) ....................................................................... 112 6.2.13.1 Keytruda for Indication 1 (Hodgkin’s Lymphoma) ............................................ 112 6.2.13.2 Keytruda for Indication 2 (Non-Hodgkin’s Lymphoma) .................................... 113 6.2.14Adcetris (Brentuximab Vedotin) ............................................................... 114 6.2.14.1 Adcetris for Indication 1 (Hodgkin’s Lymphoma) ............................................. 115 6.2.14.2 Adcetris for Indication 2 (Non-Hodgkin’s Lymphoma) ..................................... 116 6.2.15Arzerra (Ofatumumab) .............................................................................. 116 6.3 CAR-T Cell Therapy ....................................................................................... 117 6.3.1Tecartus (Brexucabtagene Autoleucel) ................................................... 118 6.3.1.1 Tecartus for Indication 1 (Acute Lymphoblastic Leukemia) ............................. 119 6.3.1.2 Tecartus for Indication 2 (Non-Hodgkin’s Lymphoma) .................................... 119 All rights reserved at BIS Research Inc. 6

  7. 6.3.2Kymriah (Tisagenlecleucel) ...................................................................... 120 6.3.2.1 Kymriah for Indication 1 (Acute Lymphoblastic Leukemia) .............................. 121 6.3.2.2 Kymriah for Indication 2 (Non-Hodgkin’s Lymphoma) ..................................... 122 6.3.3Yescarta (Axicabtagene Ciloleucel) ......................................................... 123 6.3.4Breyanzi (Lisocabtagene Maraleucel) ...................................................... 125 6.3.5Abecma (Idecabtagene Vicleucel) ............................................................ 126 7.Global Hematological Malignancies Emerging Therapeutics Market (by Potential Pipeline Products), $Million, 2020-2031 .... 127 7.1 Overview ......................................................................................................... 128 7.2 Monoclonal Antibodies ................................................................................. 129 7.2.1Teclistamab ................................................................................................ 130 7.2.2Iomab-B ...................................................................................................... 133 7.2.2.1 Preliminary Phase II Clinical Trial Results ....................................................... 135 7.2.3Ublituximab ................................................................................................ 135 7.2.4CS1001 ....................................................................................................... 137 7.3 CAR-T Cell Therapy ....................................................................................... 138 7.3.1Ciltacabtagene Autoleucel (JNJ-68284528) ............................................. 139 7.3.1.1 Phase IB-II Clinical Trial Results ..................................................................... 141 8.Global Hematological Malignancies Emerging Therapeutics Market (by Indication), $Million, 2020-2031 .............................. 142 Hematological Malignancies Emerging Therapeutics Market 8.1 Overview ......................................................................................................... 143 8.2 Leukemia ........................................................................................................ 144 8.2.1Acute Lymphoblastic Leukemia ............................................................... 144 8.2.2Chronic Lymphoblastic Leukemia ........................................................... 146 8.2.3Acute Myeloid Leukemia ........................................................................... 147 8.3 Lymphoma ...................................................................................................... 149 8.3.1Hodgkin’s Lymphoma ............................................................................... 150 8.3.2Non-Hodgkin’s Lymphoma ....................................................................... 152 8.4 Multiple Myeloma ........................................................................................... 154 9.Global Hematological Malignancies Emerging Therapeutics Market (by Region), $Million, 2020-2031 ................................... 156 All rights reserved at BIS Research Inc. 7

  8. 9.1 Overview ......................................................................................................... 157 9.2 North America ................................................................................................ 158 9.2.1U.S. ............................................................................................................. 160 9.2.1.1 Commercialized Products ................................................................................ 160 9.2.1.2 Market Size and Forecast, $Million, 2020-2031 .............................................. 162 9.2.2Canada ....................................................................................................... 163 9.2.2.1 Commercialized Products ................................................................................ 163 9.2.2.2 Market Size and Forecast, $Million, 2020-2031 .............................................. 163 1.2 Europe ............................................................................................................ 165 9.2.3Germany ..................................................................................................... 168 9.2.3.1 Market Size and Forecast, $Million, 2020-2031 .............................................. 168 9.2.4Italy ............................................................................................................. 169 9.2.4.1 Market Size and Forecast, $Million, 2020-2031 .............................................. 169 9.2.5France ......................................................................................................... 170 9.2.5.1 Market Size and Forecast, $Million, 2020-2031 .............................................. 170 9.2.6U.K. ............................................................................................................. 171 9.2.6.1 Market Size and Forecast, $Million, 2020-2031 .............................................. 171 9.2.7Spain ........................................................................................................... 172 9.2.7.1 Market Size and Forecast, $Million, 2020-2031 .............................................. 172 Hematological Malignancies Emerging Therapeutics Market 9.3 Asia-Pacific .................................................................................................... 173 9.3.1China .......................................................................................................... 175 9.3.1.1 Commercialized Products ................................................................................ 175 9.3.1.2 Market Size and Forecast, $Million, 2020-2031 .............................................. 176 9.3.2Japan .......................................................................................................... 177 9.3.2.1 Commercialized Products ................................................................................ 177 9.3.2.2 Market Size and Forecast, $Million, 2020-2031 .............................................. 178 9.3.3South Korea ............................................................................................... 178 9.3.3.1 Commercialized Products ................................................................................ 178 9.3.3.2 Market Size and Forecast, $Million, 2020-2031 .............................................. 179 9.4 Rest-of-the-World .......................................................................................... 180 All rights reserved at BIS Research Inc. 8

  9. 10.Company Profiles ..................................................................... 182 10.1Overview ......................................................................................................... 183 10.2AbbVie Inc. ..................................................................................................... 184 10.2.1Company Overview ................................................................................... 184 10.2.2Role of AbbVie Inc. in the Global Hematological Malignancies Emerging Therapeutics Market ................................................................ 184 10.2.3Financials ................................................................................................... 186 10.2.4Key Insights About Financial Health of the Company ........................... 187 10.2.5SWOT Analysis .......................................................................................... 188 10.3Amgen Inc. ..................................................................................................... 189 10.3.1Company Overview ................................................................................... 189 10.3.2Role of Amgen Inc. in the Global Hematological Malignancies Emerging Therapeutics Market ................................................................ 189 10.3.3Financials ................................................................................................... 191 10.3.4Key Insights About Financial Health of the Company ........................... 192 10.3.5SWOT Analysis .......................................................................................... 193 10.4Bristol-Myers Squibb Company ................................................................... 194 10.4.1Company Overview ................................................................................... 194 10.4.2Role of Bristol-Myers Squibb Company in the Global Hematological Malignancies Emerging Therapeutics Market ......................................... 194 Hematological Malignancies Emerging Therapeutics Market 10.4.3Financials ................................................................................................... 197 10.4.4Key Insights About Financial Health of the Company ........................... 198 10.4.5SWOT Analysis .......................................................................................... 199 10.5F. Hoffmann-La Roche Ltd. ........................................................................... 200 10.5.1Company Overview ................................................................................... 200 10.5.2Role of F. Hoffmann-La Roche Ltd. in the Global Hematological Malignancies Emerging Therapeutics Market ......................................... 200 10.5.3Financials ................................................................................................... 202 10.5.4Key Insights About Financial Health of the Company ........................... 204 10.5.5SWOT Analysis .......................................................................................... 205 10.6Gilead Sciences, Inc. ..................................................................................... 206 All rights reserved at BIS Research Inc. 9

  10. 10.6.1Company Overview ................................................................................... 206 10.6.2Role of Gilead Sciences, Inc. in the Global Hematological Malignancies Emerging Therapeutics Market ......................................... 206 10.6.3Financials ................................................................................................... 209 10.6.4Key Insights About Financial Health of the Company ........................... 211 10.6.5SWOT Analysis .......................................................................................... 212 10.7GlaxoSmithKline plc ...................................................................................... 213 10.7.1Company Overview ................................................................................... 213 10.7.2Role of GlaxoSmithKline plc in the Global Hematological Malignancies Emerging Therapeutics Market ......................................... 213 10.7.3Financials ................................................................................................... 215 10.7.4Key Insights About Financial Health of the Company ........................... 216 10.7.5SWOT Analysis .......................................................................................... 217 10.8Immune-Onc Therapeutics, Inc. ................................................................... 218 10.8.1Company Overview ................................................................................... 218 10.8.2Role of Immune-Onc Therapeutics, Inc. in the Global Hematological Malignancies Emerging Therapeutics Market ......................................... 218 10.8.3SWOT Analysis .......................................................................................... 219 10.9Johnson & Johnson Services, Inc. .............................................................. 220 10.9.1Company Overview ................................................................................... 220 Hematological Malignancies Emerging Therapeutics Market 10.9.2Role of Johnson & Johnson Services, Inc. in the Global Hematological Malignancies Emerging Therapeutics Market ............... 220 10.9.3Financials ................................................................................................... 222 10.9.4Key Insights About Financial Health of the Company ........................... 224 10.9.5SWOT Analysis .......................................................................................... 225 10.10Merck & Co., Inc. ............................................................................................ 226 10.10.1 Company Overview ............................................................................. 226 10.10.2 Role of Merck & Co., Inc. in the Global Hematological Malignancies Emerging Therapeutics Market ......................................... 226 10.10.3 Financials ............................................................................................ 228 10.10.4 Key Insights About Financial Health of the Company ..................... 230 All rights reserved at BIS Research Inc. 10

  11. 10.10.5 SWOT Analysis .................................................................................... 231 10.11Novartis International AG .............................................................................. 232 10.11.1 Company Overview ............................................................................. 232 10.11.2 Role of Novartis International AG in the Global Hematological Malignancies Emerging Therapeutics Market ......................................... 232 10.11.3 Financials ............................................................................................ 235 10.11.4 Key Insights About Financial Health of the Company ..................... 237 10.11.5 SWOT Analysis .................................................................................... 238 10.12Pfizer Inc. ........................................................................................................ 239 10.12.1 Company Overview ............................................................................. 239 10.12.2 Role of Pfizer Inc. in the Global Hematological Malignancies Emerging Therapeutics Market ................................................................ 239 10.12.3 Financials ............................................................................................ 242 10.12.4 Key Insights About Financial Health of the Company ..................... 243 10.12.5 SWOT Analysis .................................................................................... 244 10.13Sanofi S.A. ...................................................................................................... 245 10.13.1 Company Overview ............................................................................. 245 10.13.2 Role of Sanofi S.A. in the Global Hematological Malignancies Emerging Therapeutics Market ................................................................ 245 10.13.3 Financials ............................................................................................ 246 Hematological Malignancies Emerging Therapeutics Market 10.13.4 Key Insights About Financial Health of the Company ..................... 248 10.13.5 SWOT Analysis .................................................................................... 249 10.14Takeda Pharmaceutical Company Limited .................................................. 250 10.14.1 Company Overview ............................................................................. 250 10.14.2 Role of Takeda Pharmaceutical Company Limited in the Global Hematological Malignancies Emerging Therapeutics Market ............... 250 10.14.3 Financials ............................................................................................ 252 10.14.4 Key Insights About Financial Health of the Company ..................... 254 10.14.5 SWOT Analysis .................................................................................... 255 All rights reserved at BIS Research Inc. 11

  12. List of Figures Figure 1: Figure 2: Figure 3: Hematological Malignancies Drugs Approved by U.S. FDA (2015-2021) Hematological Malignancies Drugs Global Clinical Trials (by Phase) Global Hematological Malignancies Emerging Therapeutics Market (by Marketed Drugs), $Million, 2020-2031 Global Hematological Malignancies Emerging Therapeutics Market: Impact Analysis Figure 4: Figure 5: Global Hematological Malignancies Emerging Therapeutics Market (by Potential Pipeline Products), $Million, 2020-2031 Figure 6: Global Hematological Malignancies Emerging Therapeutics Market (by Indication), $Million, 2020-2031 Figure 7: Global Hematological Malignancies Emerging Therapeutics Market (by Region), $Million, 2020-2031 Global Hematological Malignancies Emerging Therapeutics Market: Segmentation Global Hematological Malignancies Emerging Therapeutics Market: Methodology Primary Research Methodology Bottom-Up Approach (Segment-Wise Analysis) Step by Step Approach Figure 8: Figure 9: Figure 10: Figure 11: Figure 12: Figure 13: Global Hematological Malignancies Emerging Therapeutics Market, $Million, 2020- 2031 Types of Hematological Malignancies Hematological Malignancies Prevalence in the U.S., 2019-2031 Hematological Malignancies Incidence in the U.S., 2019-2031 Percentage of Hematological Malignancies Prevalence (by Country), 2019 and 2031 Hematological Malignancies Prevalence in EU4+U.K., 2019-2031 Percentage of Hematological Malignancies Incidence (by Country), 2019 and 2031 Hematological Malignancies Incidence in EU4 + U.K., 2019-2031 Hematological Malignancies Prevalence in Japan, 2019-2031 Hematological Malignancies Incidence in Japan, 2019-2031 Hematological Malignancies Emerging Therapies: Developmental Phases Emerging Therapeutics for Leukemia (by Developmental Phase) Emerging Therapeutics for Lymphoma (by Developmental Phase) Emerging Therapeutics for Multiple Myeloma (by Developmental Phase) Key Steps to Navigate Crisis Recovery Process for Obtaining Marketing Authorization Current Reimbursement Scenario in Europe Prevalence of Hematological Malignancies (2015-2019) Share of Key Developments and Strategies, January 2019-December 2021 Partnerships and Alliances (by Company), January 2019-December 2021 Regulatory and Legal Activities (by Company), January 2019-December 2021 Business Expansions (by Company), January 2019-December 2021 Figure 14: Figure 15: Figure 16: Figure 17: Figure 18: Figure 19: Figure 20: Figure 21: Figure 22: Figure 23: Figure 24: Figure 25: Figure 26: Figure 27: Figure 28: Figure 29: Figure 30: Figure 31: Figure 32: Figure 33: Figure 34: Hematological Malignancies Emerging Therapeutics Market All rights reserved at BIS Research Inc. 12

  13. Figure 35: Figure 36: Figure 37: Figure 38: Figure 39: Figure 40: Figure 41: Figure 42: Figure 43: Figure 44: Figure 45: Figure 46: Merger and Acquisition Activities (by Company), January 2019-December 2021 Product Approvals (by Company), January 2019-December 2021 Market Share Analysis (by Company), 2020 Drug-Diagnostic Co-Development Model FDA Guidance Pertaining to CDx Approval Components Considered for Clinical Evidence as per the IVDR Medical Device Regulatory Approval Process in China Process of Medical Device Designation by MHLW and PMDA Medical Device Regulatory Approval Process in South Korea Classification of IVD Devices Medical Device (IVDs) Regulatory Approval Process in Australia Global Hematological Malignancies Emerging Therapeutics Market (by Marketed Drugs), $Million, 2020-2031 Figure 47: Global Hematological Malignancies Emerging Therapeutics Market (by Monoclonal Antibodies), $Million, 2020-2031 Global Revenue for Blincyto, $Million, 2020-2031 Global Revenue for Besponsa, $Million, 2020-2031 Global Revenue for Lumoxiti, $Million, 2020-2031 Global Revenue for Mylotarg, $Million, 2020-2031 Global Revenue for Opdivo, $Million, 2020-2031 Global Revenue for AiRuiKa, $Million, 2020-2031 Global Revenue for Tyvyt, $Million, 2020-2031 Global Revenue for Tislelizumab, $Million, 2020-2031 Global Revenue for Gazyva, $Million, 2020-2031 Global Revenue for Zynlonta, $Million, 2020-2031 Global Revenue for Darzalex, $Million, 2020-2031 Global Revenue for Blenrep, $Million, 2020-2031 Global Revenue for Keytruda, $Million, 2020-2031 Global Revenue for Keytruda (Hodgkin’s Lymphoma), $Million, 2020-2031 Global Revenue for Keytruda (Non-Hodgkin’s Lymphoma), $Million, 2020-2031 Global Revenue for Adcetris, $Million, 2020-2031 Global Revenue for Adcetris (Hodgkin’s Lymphoma), $Million, 2020-2031 Global Revenue for Adcetris (Non-Hodgkin’s Lymphoma), $Million, 2020-2031 Figure 48: Figure 49: Figure 50: Figure 51: Figure 52: Figure 53: Figure 54: Figure 55: Figure 56: Figure 57: Figure 58: Figure 59: Figure 60: Figure 61: Figure 62: Figure 63: Figure 64: Figure 65: Figure 66: Hematological Malignancies Emerging Therapeutics Market Global Hematological Malignancies Emerging Therapeutics Market (by CAR-T Cell Therapy), $Million, 2020-2031 Global Revenue for Tecartus, $Million, 2020-2031 Global Revenue for Tecartus (Acute Lymphoblastic Leukemia), $Million, 2020-2031 Global Revenue for Tecartus (Non-Hodgkin’s Lymphoma), $Million, 2020-2031 Global Revenue for Kymriah, $Million, 2020-2031 Global Revenue for Kymriah (Acute Lymphoblastic Leukemia), $Million, 2020-2031 Figure 67: Figure 68: Figure 69: Figure 70: Figure 71: All rights reserved at BIS Research Inc. 13

  14. Figure 72: Figure 73: Figure 74: Figure 75: Figure 76: Global Revenue for Kymriah (Non-Hodgkin’s Lymphoma), $Million, 2020-2031 Global Revenue for Yescarta, $Million, 2020-2031 Global Revenue for Breyanzi, $Million, 2020-2031 Global Revenue for Abecma, $Million, 2020-2031 Global Hematological Malignancies Emerging Therapeutics Market (by Potential Pipeline Products), $Million, 2020-2031 Figure 77: Global Hematological Malignancies Emerging Therapeutics Market (by Potential Pipeline Products), by Monoclonal Antibodies), $Million, 2020-2031 Global Revenue for Teclistamab, $Million, 2020-2031 Teclistamab Phase I Clinical Trial Design for Relapsed or Refractory Multiple Myeloma Figure 78: Figure 79: Figure 80: Teclistamab Phase II Clinical Trial Design for Relapsed or Refractory Multiple Myeloma Global Revenue for Iomab-B, $Million, 2020-2031 Figure 81: Figure 82: Iomab-B Phase III Clinical Trial Design for Relapsed or Refractory Acute Myeloid Leukemia Global Revenue for Ublituximab, $Million, 2020-2031 Figure 83: Figure 84: Ublituximab Phase I/II Clinical Trial Design for Relapsed or Refractory B-Cell Non- Hodgkin’s Lymphoma Global Revenue for CS1001, $Million, 2020-2031 Figure 85: Figure 86: CS1001 Phase II Clinical Trial Design for Relapsed or Refractory B-cell Hodgkin’s Lymphoma Global Revenue for Ciltacabtagene Autoleucel, $Million, 2020-2031 Figure 87: Figure 88: Ciltacabtagene Autoleucel (JNJ-68284528) Phase Ib-II Clinical Trial Design for Relapsed or Refractory Multiple Myeloma Figure 89: Global Hematological Malignancies Emerging Therapeutics Market (by Indication), $Million, 2020-2031 Figure 90: Global Hematological Malignancies Emerging Therapeutics Market (by Indication, by Leukemia), $Million, 2020-2031 Hematological Malignancies Emerging Therapeutics Market Figure 91: Global Hematological Malignancies Emerging Therapeutics Market (by Acute Lymphoblastic Leukemia), $Million, 2020-2031 Figure 92: Global Hematological Malignancies Emerging Therapeutics Market (by Chronic Lymphoblastic Leukemia), $Million, 2020-2031 Figure 93: Global Hematological Malignancies Emerging Therapeutics Market (by Acute Myeloid Leukemia), $Million, 2020-2031 Figure 94: Global Hematological Malignancies Emerging Therapeutics Market (by Lymphoma), $Million, 2020-2031 Figure 95: Global Hematological Malignancies Emerging Therapeutics Market (by Hodgkin’s Lymphoma), $Million, 2020-2031 Figure 96: Global Hematological Malignancies Emerging Therapeutics Market (by Non-Hodgkin’s Lymphoma), $Million, 2020-2031 Figure 97: Global Hematological Malignancies Emerging Therapeutics Market (by Multiple Myeloma), $Million, 2020-2031 Figure 98: Global Hematological Malignancies Emerging Therapeutics Market (by Region), $Million, 2020-2031 Figure 99: North America Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031 All rights reserved at BIS Research Inc. 14

  15. Figure 100: Figure 101: North America: Market Dynamics North America Hematological Malignancies Emerging Therapeutics Market, (by Country), $Million, 2020 and 2031 U.S. Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031 Figure 102: Figure 103: Canada Hematological Malignancies Emerging Therapeutics Market, $Million, 2020- 2031 Figure 104: Europe Hematological Malignancies Emerging Therapeutics Market, $Million, 2020- 2031 Europe: Market Dynamics Figure 105: Figure 106: Europe Hematological Malignancies Emerging Therapeutics Market, (by Country), $Million, 2020 and 2031 Figure 107: Germany Hematological Malignancies Emerging Therapeutics Market, $Million, 2020- 2031 Italy Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031 Figure 108: Figure 109: France Hematological Malignancies Emerging Therapeutics Market, $Million, 2020- 2031 U.K. Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031 Figure 110: Figure 111: Spain Hematological Malignancies Emerging Therapeutics Market, $Million, 2020- 2031 Figure 112: Asia-Pacific Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031 Asia-Pacific: Market Dynamics Figure 113: Figure 114: Asia-Pacific Hematological Malignancies Emerging Therapeutics Market (by Country), $Million, 2020 and 2031 Figure 115: China Hematological Malignancies Emerging Therapeutics Market, $Million, 2020- 2031 Figure 116: Japan Hematological Malignancies Emerging Therapeutics Market, $Million, 2020- 2031 Figure 117: South Korea Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031 Hematological Malignancies Emerging Therapeutics Market Figure 118: Rest-of-the-World Hematological Malignancies Emerging Therapeutics Market, $Million, 2020-2031 Total Number of Companies Profiled AbbVie Inc.: Pre-Clinical and Clinical Assets AbbVie Inc.: Overall Financials, $Million, 2018-2020 AbbVie, Inc.: Revenue (by Region), $Million, 2018-2020 AbbVie Inc.: R&D Expenditure, $Million, 2018-2020 AbbVie Inc.: SWOT Analysis Amgen Inc.: Commercialized Therapy Amgen Inc.: Pre-Clinical and Clinical Assets Amgen Inc.: Overall Financials, $Million, 2018-2020 Amgen Inc.: Revenue (by Region), $Million, 2018-2020 Amgen Inc.: R&D Expenditure, $Million, 2018-2020 Amgen Inc.: SWOT Analysis Figure 119: Figure 120: Figure 121: Figure 122: Figure 123: Figure 124: Figure 125: Figure 126: Figure 127: Figure 128: Figure 129: Figure 130: All rights reserved at BIS Research Inc. 15

  16. Figure 131: Figure 132: Figure 133: Figure 134: Figure 135: Figure 136: Figure 137: Figure 138: Figure 139: Figure 140: Figure 141: Figure 142: Figure 143: Figure 144: Figure 145: Figure 146: Figure 147: Figure 148: Figure 149: Figure 150: Figure 151: Figure 152: Figure 153: Figure 154: Figure 155: Figure 156: Figure 157: Figure 158: Figure 159: Figure 160: Figure 161: Figure 162: Figure 163: Figure 164: Figure 165: Figure 166: Figure 167: Figure 168: Figure 169: Bristol-Myers Squibb Company: Commercialized Therapies Bristol-Myers Squibb Company: Pre-Clinical and Clinical Assets Bristol-Myers Squibb Company: Overall Financials, $Million, 2018-2020 Bristol-Myers Squibb Company: Revenue (by Region), $Million, 2018-2020 Bristol-Myers Squibb Company: R&D Expenditure, $Million, 2018-2020 Bristol-Myers Squibb Company: SWOT Analysis F. Hoffmann-La Roche Ltd.: Commercialized Therapy F. Hoffmann-La Roche Ltd.: Pre-Clinical and Clinical Assets F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2018-2020 F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2018-2020 F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2018-2020 F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2018-2020 F. Hoffmann-La Roche Ltd.: SWOT Analysis Gilead Sciences, Inc.: Commercialized Therapies Gilead Sciences, Inc.: Pre-Clinical and Clinical Assets Gilead Sciences, Inc.: Overall Financials, $Million, 2018-2020 Gilead Sciences, Inc.: Revenue (by Segment), $Million, 2018-2020 Gilead Sciences, Inc.: Revenue (by Region), $Million, 2018-2020 Gilead Sciences, Inc.: R&D Expenditure, $Million, 2018-2020 Gilead Sciences, Inc.: SWOT Analysis GlaxoSmithKline plc: Commercialized Therapy GlaxoSmithKline plc: Overall Financials, $Million, 2018-2020 GlaxoSmithKline plc: Revenue (by Segment), $Million, 2018-2020 GlaxoSmithKline plc: Revenue (by Region), $Million, 2018-2020 GlaxoSmithKline plc: R&D Expenditure, $Million, 2018-2020 GlaxoSmithKline plc: SWOT Analysis Immune-Onc Therapeutics, Inc.: Pre-Clinical and Clinical Assets Immune-Onc Therapeutics, Inc.: SWOT Analysis Johnson & Johnson Services, Inc.: Commercialized Therapy Johnson & Johnson Services, Inc.: Pre-Clinical and Clinical Assets Johnson & Johnson Services, Inc.: Overall Financials, $Million, 2018-2020 Johnson & Johnson Services, Inc.: Revenue (by Segment), $Million, 2018-2020 Johnson & Johnson Services, Inc.: Revenue (by Region), $Million, 2018-2020 Johnson & Johnson Services, Inc.: R&D Expenditure, $Million, 2018-2020 Johnson & Johnson Services, Inc.: SWOT Analysis Merck & Co., Inc.: Commercialized Therapy Merck & Co., Inc.: Pre-Clinical and Clinical Assets Merck & Co., Inc.: Overall Financials, $Million, 2018-2020 Merck & Co., Inc.: Revenue (by Segment), $Million, 2018-2020 Hematological Malignancies Emerging Therapeutics Market All rights reserved at BIS Research Inc. 16

  17. Figure 170: Figure 171: Figure 172: Figure 173: Figure 174: Figure 175: Figure 176: Figure 177: Figure 178: Figure 179: Figure 180: Figure 181: Figure 182: Figure 183: Figure 184: Figure 185: Figure 186: Figure 187: Figure 188: Figure 189: Figure 190: Figure 191: Figure 192: Figure 193: Figure 194: Figure 195: Figure 196: Figure 197: Merck & Co., Inc.: Revenue (by Region), $Million, 2018-2020 Merck & Co., Inc.: R&D Expenditure, $Million, 2018-2020 Merck & Co., Inc.: SWOT Analysis Novartis International AG: Commercialized Therapy Novartis International AG: Pre-Clinical and Clinical Assets Novartis International AG: Overall Financials, $Million, 2018-2020 Novartis International AG: Revenue (by Segment), $Million, 2018-2020 Novartis International AG: Revenue (by Region), $Million, 2018-2020 Novartis International AG: R&D Expenditure, $Million, 2018-2020 Novartis International AG: SWOT Analysis Pfizer Inc.: Commercialized Therapy Pfizer Inc.: Pre-Clinical and Clinical Assets Pfizer Inc.: Overall Financials, $Million, 2018-2020 Pfizer Inc.: Revenue (by Region), $Million, 2018-2020 Pfizer Inc.: R&D Expenditure, $Million, 2018-2020 Pfizer Inc.: SWOT Analysis Sanofi S.A.: Pre-Clinical and Clinical Assets Sanofi SA: Overall Financials, $Million, 2018-2020 Sanofi S.A.: Revenue (by Segment), $Million, 2018-2020 Sanofi S.A.: Revenue (by Region), $Million, 2018-2020 Sanofi S.A.: R&D Expenditure, $Million, 2018-2020 Sanofi S.A.: SWOT Analysis Takeda Pharmaceutical Company Limited.: Commercialized Therapy Takeda Pharmaceutical Company Limited: Pre-Clinical and Clinical Assets Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2018-2020 Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2018-2020 Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2018-2020 Takeda Pharmaceutical Company Limited: SWOT Analysis Hematological Malignancies Emerging Therapeutics Market All rights reserved at BIS Research Inc. 17

  18. List of Tables Table 1: Table 2: Table 3: Table 4: Table 5: Table 6: Table 7: Table 8: Table 9: Table 10: Table 11: Table 12: Table 13: Table 14: Table 15: Table 16: Table 17: Table 18: Table 19: Table 20: Table 21: Table 22: Table 23: Cost of Selective Hematological Malignancies Therapeutics in U.S. Likert Scale Impact Analysis of Market Drivers Impact Analysis of Market Restraints Prominent FDA-Approved CDx Tests for Hematological Malignancies Classification Rules of IVDs under IVDR Registration Criteria for IVD Medical Devices as per the NMPA Hematological Malignancies Therapeutics Drugs for Acute Lymphoblastic Leukemia Hematological Malignancies Therapeutics Drugs for Chronic Lymphoblastic Leukemia Hematological Malignancies Therapeutics Drugs for Acute Myeloid Leukemia Hematological Malignancies Therapeutics Drugs for Hodgkin’s Lymphoma Hematological Malignancies Therapeutics Drugs for Non-Hodgkin’s Lymphoma Hematological Malignancies Therapeutics Drugs for Multiple Myeloma List of Selective Hematological Malignancies Commercialized Products in the U.S. Canada Hematological Malignancies Commercialized Products List of Selective Hematological Malignancies Commercialized Products in Europe List of Selective Hematological Malignancies Commercialized Products in China List of Selective Hematological Malignancies Commercialized Products in Japan List of Selective Hematological Malignancies Commercialized Products in South Korea Blincyto (Blinatumomab): Indications Opdivo (Nivolumab) and Breyanzi (Lisocabtagene Maraleucel): Indications Gazyva (Obinutuzumab): Indications Yescarta (Axicabtagene ciloleucel) and Tecartus (Brexucabtagene autoleucel): Indications Blenrep (Belantamab mafodotin): Indications Darzalex (Daratumumab): Indications Keytruda (Pembrolizumab): Indications Kymriah (Tisagenlecleucel): Indications Hematological Malignancies Emerging Therapeutics Market Table 24: Table 25: Table 26: Table 27: Table 28: Besponsa (Inotuzumab ozogamicin) and Mylotarg (Gemtuzumab Ozogamicin): Indications Adcetris (Brentuximab vedotin): Indications Table 29: All rights reserved at BIS Research Inc. 18

  19. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Hematological Malignancies Emerging Therapeutics Market Know More Know More Know More Know More All rights reserved at BIS Research Inc. 19

  20. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates, and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 Hematological Malignancies Emerging Therapeutics Market All rights reserved at BIS Research Inc. 20

  21. Hematological Malignancies Emerging Therapeutics Market BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com All rights reserved at BIS Research Inc. 21

More Related